Relevant bibliographies by topics / Oral vaccines

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Oral vaccines'

Author: Grafiati
Published: 4 June 2021
Last updated: 7 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Oral vaccines.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Oral vaccines"

1

Zhu, Qing, and Jay A. Berzofsky. "Oral vaccines." Gut Microbes 4, no. 3 (May 2013): 246–52. http://dx.doi.org/10.4161/gmic.24197.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Van der Weken, Hans, Eric Cox, and Bert Devriendt. "Advances in Oral Subunit Vaccine Design." Vaccines 9, no. 1 (December 22, 2020): 1. http://dx.doi.org/10.3390/vaccines9010001.

Full text
Abstract:
Many pathogens invade the host at the intestinal surface. To protect against these enteropathogens, the induction of intestinal secretory IgA (SIgA) responses is paramount. While systemic vaccination provides strong systemic immune responses, oral vaccination is the most efficient way to trigger protective SIgA responses. However, the development of oral vaccines, especially oral subunit vaccines, is challenging due to mechanisms inherent to the gut. Oral vaccines need to survive the harsh environment in the gastrointestinal tract, characterized by low pH and intestinal proteases and need to reach the gut-associated lymphoid tissues, which are protected by chemical and physical barriers that prevent efficient uptake. Furthermore, they need to surmount default tolerogenic responses present in the gut, resulting in suppression of immunity or tolerance. Several strategies have been developed to tackle these hurdles, such as delivery systems that protect vaccine antigens from degradation, strong mucosal adjuvants that induce robust immune responses and targeting approaches that aim to selectively deliver vaccine antigens towards specific immune cell populations. In this review, we discuss recent advances in oral vaccine design to enable the induction of robust gut immunity and highlight that the development of next generation oral subunit vaccines will require approaches that combines these solutions.
APA, Harvard, Vancouver, ISO, and other styles
3

Coffey, Jacob William, Gaurav Das Gaiha, and Giovanni Traverso. "Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics." Annual Review of Pharmacology and Toxicology 61, no. 1 (January 6, 2021): 517–40. http://dx.doi.org/10.1146/annurev-pharmtox-030320-092348.

Full text
Abstract:
Oral vaccination enables pain-free and self-administrable vaccine delivery for rapid mass vaccination during pandemic outbreaks. Furthermore, it elicits systemic and mucosal immune responses. This protects against infection at mucosal surfaces, which may further enhance protection and minimize the spread of disease. The gastrointestinal (GI) tract presents a number of prospective mucosal inductive sites for vaccine targeting, including the oral cavity, stomach, and small intestine. However, currently available oral vaccines are effectively limited to live-attenuated and inactivated vaccines against enteric diseases. The GI tract poses a number of challenges,including degradative processes that digest biologics and mucosal barriers that limit their absorption. This review summarizes the approaches currently under development and future opportunities for oral vaccine delivery to established (intestinal) and relatively new (oral cavity, stomach) mucosal targets. Special consideration is given to recent advances in oral biologic delivery that offer promise as future platforms for the administration of oral vaccines.
APA, Harvard, Vancouver, ISO, and other styles
4

Folorunso, Olufemi Samuel, and Olihile M. Sebolai. "Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines." Vaccines 8, no. 3 (June 27, 2020): 341. http://dx.doi.org/10.3390/vaccines8030341.

Full text
Abstract:
Safety, efficacy, and cost-effectiveness are paramount to vaccine development. Following the isolation of rotavirus particles in 1969 and its evidence as an aetiology of severe dehydrating diarrhoea in infants and young children worldwide, the quest to find not only an acceptable and reliable but cost-effective vaccine has continued until now. Four live-attenuated oral rotavirus vaccines (LAORoVs) (Rotarix®, RotaTeq®, Rotavac®, and RotaSIIL®) have been developed and licensed to be used against all forms of rotavirus-associated infection. The efficacy of these vaccines is more obvious in the high-income countries (HIC) compared with the low- to middle-income countries (LMICs); however, the impact is far exceeding in the low-income countries (LICs). Despite the rotavirus vaccine efficacy and effectiveness, more than 90 countries (mostly Asia, America, and Europe) are yet to implement any of these vaccines. Implementation of these vaccines has continued to suffer a setback in these countries due to the vaccine cost, policy, discharging of strategic preventive measures, and infrastructures. This review reappraises the impacts and effectiveness of the current live-attenuated oral rotavirus vaccines from many representative countries of the globe. It examines the problems associated with the low efficacy of these vaccines and the way forward. Lastly, forefront efforts put forward to develop initial procedures for oral rotavirus vaccines were examined and re-connected to today vaccines.
APA, Harvard, Vancouver, ISO, and other styles
5

Faruck, Mohammad O., Prashamsa Koirala, Jieru Yang, Michael J. D’Occhio, Mariusz Skwarczynski, and Istvan Toth. "Polyacrylate-GnRH Peptide Conjugate as an Oral Contraceptive Vaccine Candidate." Pharmaceutics 13, no. 7 (July 15, 2021): 1081. http://dx.doi.org/10.3390/pharmaceutics13071081.

Full text
Abstract:
Contraceptive vaccines are designed to elicit immune responses against major components of animal reproductive systems. These vaccines, which are most commonly administered via injection, typically target gonadotropin-releasing hormone (GnRH). However, the need to restrain animals for treatment limits the field applications of injectable vaccines. Oral administration would broaden vaccine applicability. We explored contraceptive vaccine candidates composed of GnRH peptide hormone, universal T helper PADRE (P), and a poly(methylacrylate) (PMA)-based delivery system. When self-assembled into nanoparticles, PMA-P-GnRH induced the production of high IgG titers after subcutaneous and oral administration in mice. PADRE was then replaced with pig T helper derived from the swine flu virus, and the vaccine was tested in pigs. High levels of systemic antibodies were produced in pigs after both injection and oral administration of the vaccine. In conclusion, we developed a simple peptide–polymer conjugate that shows promise as an effective, adjuvant-free, oral GnRH-based contraceptive vaccine.
APA, Harvard, Vancouver, ISO, and other styles
6

Hanna, Jeffrey, HarryF Hull, Jong Wook Lee, PeterA Patriarca, SamuelL Katz, and RobertT Chen. "Oral poliomyelitis vaccines." Lancet 347, no. 9013 (May 1996): 1495–96. http://dx.doi.org/10.1016/s0140-6736(96)91736-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kabir, Shahjahan. "Critical Analysis of Compositions and Protective Efficacies of Oral Killed Cholera Vaccines." Clinical and Vaccine Immunology 21, no. 9 (July 23, 2014): 1195–205. http://dx.doi.org/10.1128/cvi.00378-14.

Full text
Abstract:
ABSTRACTTwo cholera vaccines, sold as Shanchol and Dukoral, are currently available. This review presents a critical analysis of the protective efficacies of these vaccines. Children under 5 years of age are very vulnerable to cholera and account for the highest incidence of cholera cases and more than half of the resulting deaths. Both Shanchol and Dukoral are two-spaced-dose oral vaccines comprising large numbers of killed cholera bacteria. The former containsVibrio choleraeO1 and O139 cells, and the latter containsV. choleraeO1 cells with the recombinant B subunit of cholera toxin. In a field trial in Kolkata (India), Shanchol, the preferred vaccine, protected 45% of the test subjects in all of the age groups and only 17% of the children under 5 years of age during the first year of surveillance. In a field trial in Peru, two spaced doses of Dukoral offered negative protection in children under 5 years of age and little protection (15%) in vaccinees over 6 years of age during the first year of surveillance. Little is known about Dukoral's long-term protective efficacy. Both of these vaccines have questionable compositions, usingV. choleraeO1 strains isolated in 1947 that have been inactivated by heat and formalin treatments that may denature protein. Immunological studies revealed Dukoral's reduced and short-lived efficacy, as measured by several immunological endpoints. Various factors, such as the necessity for multiple doses, poor protection of children under 5 years of age, the requirement of a cold supply chain, production costs, and complex logistics of vaccine delivery, greatly reduce the suitability of either of these vaccines for endemic or epidemic cholera control in resource-poor settings.
APA, Harvard, Vancouver, ISO, and other styles
8

Bhairy, Srinivas Rajesham, and Rajashree Shreeram Hirlekar. "EDIBLE VACCINES: AN ADVANCEMENT IN ORAL IMMUNIZATION." Asian Journal of Pharmaceutical and Clinical Research 10, no. 2 (February 1, 2017): 71. http://dx.doi.org/10.22159/ajpcr.2017.v10i2.15825.

Full text
Abstract:
Vaccines represent a useful contribution to the field of biotechnology as they supply protection against various diseases. But, the major obstacle to oral vaccination is the digestion of macromolecule antigenic protein within the stomach due to extremely acidic pH. To address this issue, scientist Arntzen introduced the concept of edible vaccines. Edible vaccines are prepared by using the science of genetic engineering in which the selected genes are introduced into the plants by means of various methods. The transgenic plant is then induced to manufacture the encoded protein which acts as a vaccine. Owing to its low cost, it will be affordable for developing countries like India. Edible vaccines are used to treat various diseases like malaria, measles, hepatitis B, stopping autoimmunity in type-1 diabetes, cholera, enterotoxicogenic E.coli (ETEC), HIV and anthrax. This review comprises mechanism of action, methods of development, candidate plants, applications, clinical trials and patents of edible vaccines.Keywords: Edible vaccines, Antigens, Oral immunization, Immunity.
APA, Harvard, Vancouver, ISO, and other styles
9

Chatfield, S. N., M. Roberts, G. Dougan, C. Hormaeche, and C. M. A. Khan. "The development of oral vaccines against parasitic diseases utilizing live attenuatedSalmonella." Parasitology 110, S1 (March 1995): S17—S24. http://dx.doi.org/10.1017/s0031182000001451.

Full text
Abstract:
SummaryGenetically defined, live attenuatedSalmonellavaccines are proving useful both as oral vaccines against salmonellosis and for the development of multivalent vaccines based on the expression of heterologous antigens in such strains. Several candidate attenuatedS. typhistrains are at present being evaluated as new single dose oral typhoid vaccines in human volunteers. The emergence of such a vaccine will facilitate the development of multivalent vaccines for humans. Many antigens from different infectious organisms have been expressed in attenuatedSalmonella. A focus of this work has been on developing vaccines against parasitic diseases. This review will summarize the efforts that have been made in this area.
APA, Harvard, Vancouver, ISO, and other styles
10

Kang, Sung, Seok Hong, Yong-Kyu Lee, and Sungpil Cho. "Oral Vaccine Delivery for Intestinal Immunity—Biological Basis, Barriers, Delivery System, and M Cell Targeting." Polymers 10, no. 9 (August 27, 2018): 948. http://dx.doi.org/10.3390/polym10090948.

Full text
Abstract:
Most currently available commercial vaccines are delivered by systemic injection. However, needle-free oral vaccine delivery is currently of great interest for several reasons, including the ability to elicit mucosal immune responses, ease of administration, and the relatively improved safety. This review summarizes the biological basis, various physiological and immunological barriers, current delivery systems with delivery criteria, and suggestions for strategies to enhance the delivery of oral vaccines. In oral vaccine delivery, basic requirements are the protection of antigens from the GI environment, targeting of M cells and activation of the innate immune response. Approaches to address these requirements aim to provide new vaccines and delivery systems that mimic the pathogen’s properties, which are capable of eliciting a protective mucosal immune response and a systemic immune response and that make an impact on current oral vaccine development.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Oral vaccines"

1

New, James Stewart. "Plant-made oral vaccines evaluation of capsules." Honors in the Major Thesis, University of Central Florida, 2011. http://digital.library.ucf.edu/cdm/ref/collection/ETH/id/493.

Full text
Abstract:
Antigen expression through the Chloroplast Transformation Technology (CTT) produces bioencapsulated subunit-vaccines, capable of eliciting immune responses when delivered orally. Considerable challenges to effective plant-based vaccines are the normalization of dosage and preservation of accumulated antigen, which is complicated by variable high water content and protease activity. This study critically examines the efficacy of lyophilization in dehydrating plant-tissues and preserving plant-derived antigens with vaccine potential. Lyophilization was optimized through gravimetric analysis using lettuce expressing Protective Antigen (PA) of Bacillus anthracis (LS-HPAG) and the human autoantigen Proinsulin (Pins) fused to Cholera toxin subunit B (LS-CTB-Pins). Lyophilization for 48-hours was sufficient treatment to reduce lettuce to 4.57% of its original weight, which retained .058% water content in the bound state; these levels corresponded with oven-dried controls while antigen was stabilized for over a year of storage at room temperature. A simulated gastric fluid assay was applied to evaluate stability of plant derived antigens during digestion. It was observed that lettuce plant cells conferred protection through antigen bioencapsulation for up to an hour under enzymatic digestive conditions. LS-HPAG immunogenicity was then demonstrated through the induction of a PA-specific IgG response by through oral boosting of C57/BL6 test mice. Survival during toxin challenge demonstrated a protective immune response if 40% of animal immunized by plant-derived PA. Lastly, the inclusion of excipient and adjuvant additives will be considered and utilized for the development of prototype vaccine capsule formulations.
B.S.
Bachelors
Medicine
Molecular Biology and Microbiology
APA, Harvard, Vancouver, ISO, and other styles
2

Morgan, Suzanne M. "Development of oral vaccines : evaluation of polymer-peptide conjugates." Thesis, Keele University, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.333420.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bauer, Heike. "Towards a second generation of Salmonella-mediated oral DNA vaccines." [S.l.] : [s.n.], 2004. http://deposit.ddb.de/cgi-bin/dokserv?idn=972155368.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ashby, Deborah. "Feasibility of testing recombinant oral attenuated Salmonella vaccines in rabbits." Thesis, University of Ottawa (Canada), 2002. http://hdl.handle.net/10393/6248.

Full text
Abstract:
An effective vaccine against chancroid could take the place of therapeutic control programs, offering long-lasting protection without the risk of widespread drug resistance. Orally administered recombinant attenuated Salmonella strains are used as vaccine vectors to deliver heterologous, pathogen-derived antigens to intestinal mucosal associated lymphoid tissue, and to provide vaccine adjuvancy. Chancroid vaccines are tested in a temperature-dependent rabbit model of experimental H. ducreyi infection. However, testing of recombinant attenuated Salmonella strains as vaccine vectors has never been done in rabbits; it is usually done in mice. Anatomic and physiologic differences may limit this approach to the demonstration of vaccine feasibility in rabbits. A three-part study was designed to assess the feasibility of testing attenuated Salmonella vector vaccines in rabbits. The questions asked were, (1) what is the maximum tolerated oral dose and minimum immunogenic oral dose of attenuated Salmonella in rabbits, (2) can a recombinant antigen expressed in the attenuated vector be recognized by the rabbit immune system, and (3) will experimental H. ducreyi infection in rabbits after oral Salmonella vaccination function as a comparative quantitative virulence assay to permit vaccine evaluation? (Abstract shortened by UMI.)
APA, Harvard, Vancouver, ISO, and other styles
5

Tyrer, Peter Charles, and n/a. "Targeting M-cells for oral vaccine delivery." University of Canberra. Health Sciences, 2004. http://erl.canberra.edu.au./public/adt-AUC20060427.122012.

Full text
Abstract:
An in vitro model of the follicle-associated epithelia that overlie the Peyer's patches of the small intestine was developed and validated to examine the mechanisms of mucosal antigen sampling. This model displays many phenotypic and physiological characteristics of M cells including apical expression of [alpha]5[beta]l integrin and enhanced energy dependent participate transport. CD4+ T-cells were shown to be an important influence on the development of Mlike cells. The model was used to examine the M cell mediated uptake of several putative whole-cell killed bacterial vaccines. Greater numbers of non-typeable Haemophilus influenzae NTHi 289, NTHi 2019, Escherichia coli 075 HMN and Streptococcus pneumoniae were transported by model M cells compared to control Caco-2 enterocyte-like cells. Studies in isolated murine intestine segments confirmed the selective uptake of NTHi 289 and Escherichia coli demonstrating that intestinal mucosal sampling of these antigens is performed by M cells. Pseudomonas aeruginosa was not absorbed as whole cell bacteria but as soluble antigen, as indicated by the presence of bacterial DNA in the cytoplasm of epithelial cells. These results suggest that bacteria such as NTHi and E. coli are sampled by the mucosal immune system in a different manner to that of bacteria such as Pseudomonas. A number of potential cell surface receptors were investigated to identify which molecules are responsible for intestinal uptake whole-cell killed bacteria. Immunofluorescence studies detected the presence of toll-like receptor-2, toll-like receptor-4, PAF-R and [alpha]5[beta]l integrin on in vitro M-like cell cultures. Examinations of murine intestine confirmed the presence of TLR-4 and PAF-R. TLR-4 was found in small quantities and on M cells. In contrast to the M cell model, TLR-2 expression in the murine intestine was sparse. Receptor inhibition experiments provided evidence for the involvement of TLR-4, PAF-R and [alpha]5[beta]l integrin in M cell uptake of killed bacteria both in vitro and in vivo. This thesis has contributed valuable information regarding the mechanisms of uptake of whole-cell killed bacteria by the intestinal mucosal immune system. For the first time, M cell sampling of whole-cell killed bacteria has been demonstrated. Furthermore, the receptors involved in these processes have been identified. This information will be of great use in the development and optimisation of new oral vaccines.
APA, Harvard, Vancouver, ISO, and other styles
6

Mahbubani, Krishnaa Trishna Ashok. "Vehicles for the oral delivery of live bacteria." Thesis, University of Cambridge, 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.608290.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Maloy, Kevin Joseph. "The basis of the oral and parenteral adjuvant properties of immune stimulating complexes (ISCOMS)." Thesis, University of Glasgow, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.321045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Krüger, Carina. "Passive immunization against oral pathogens /." Stockholm, 2004. http://diss.kib.ki.se/2004/91-7349-960-9/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Darton, Thomas C. "Application of a challenge model to assess the protective efficacy of oral typhoid vaccines in humans." Thesis, University of Oxford, 2014. https://ora.ox.ac.uk/objects/uuid:4f0dfdf5-d2b0-402d-8910-e17c72eb832c.

Full text
Abstract:
Human infection by Salmonella Typhi has been occurring for the last 50,000 years and still accounts for ∼ 22million new cases each year worldwide. Through faeco-oral transmission, this human-restricted infection disproportionately affects the most impoverished sections of endemic communities where adequate sanitation infrastructure and effective vaccination approaches are lacking. Development of new control measures to accurately measure the burden of disease and to prevent infection with new vaccine candidates are hindered by an incomplete understanding of host-pathogen interactions and of what constitutes a protective human response after exposure. In this thesis I describe the practical application of a recently developed human challenge model of typhoid infection in assessing new control measures, including the evaluation of the oral single-dose vaccine candidate, M01ZH09. In performing a large, double-blind, placebo-controlled study, I was able to measure the direct protective efficacy (PE) of vaccination with either M01ZH09 or 3-dose Ty21a by performing human challenge with 104CFU Salmonella Typhi, Quailes strain, 28-days later. Using clinical and microbiological definitions to confirm typhoid diagnosis during a 14-day period after ingestion, I found insignificant levels of protection afforded by a single dose of M01ZH09 (12.9%), and a low PE after Ty21a vaccination (35%), demonstrating the stringency of the model and the endpoints used. Many additional insights into pathogen dynamics and host responses were found highlighting several important characteristics of oral vaccination. M01ZH09 was highly immunogenic, and both active vaccines significantly reduced bacterial burden (bacteraemia and stool shedding) while having no effect on symptomatic severity of infection in those diagnosed. M01ZH09 receipt resulted in a significantly longer incubation period, suggesting underlying protective responses were being generated. Further findings included the first objective demonstration of primary bacteraemia occurring after typhoid exposure, and frequent asymptomatic infection or stool shedding in those exposed but remaining well. Overall, these data also demonstrated significant protective effects against challenge by anti-Vi antibody status and age at baseline. Taking these factors into account, M01ZH09 and Ty21a vaccination did convey an overall protective advantage against developing typhoid infection, each reducing the risk of diagnosis by ~two-fold during the challenge period.
APA, Harvard, Vancouver, ISO, and other styles
10

Zheng, Songyue, and 郑嵩岳. "Comparative immunological evaluation of recombinant Salmonella typhimurium strains expressing model antigens as live oral vaccines." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B49617734.

Full text
Abstract:
Despite the development of various systems to generate live recombinant Salmonella Typhimurium vaccine strains, little work has been performed to systematically evaluate and compare their relative immunogenicity. Such information would provide invaluable guidance for the future rational design of live recombinant Salmonella oral vaccines. Here, a series of recombinant Salmonella Typhimurium strains were constructed to express either the enhanced green fluorescent protein (EGFP) or a fragment of the hemagglutinin (HA) protein from the H5N1 influenza virus, as model antigens. To investigate different delivery and expression methods, antigens were expressed from the chromosome, from high or low-copy plasmids, or encoded on a eukaryotic expression plasmid. Antigens were targeted for expression in the cytoplasm, or the outer membrane. In addition, combinations of two expression strategies were employed to evaluate the efficacy of combined delivery approaches. After investigating in vitro and in vivo antigen expression, growth and infection abilities, the immunogenicity of the constructed recombinant Salmonella strains was evaluated and compared in mice. Using soluble model antigen EGFP, my results indicated that vaccine strains with high and stable antigen expression exhibited high B cell responses, while eukaryotic expression or colonization with good construct stability is critical for T cell responses. For insoluble antigen model HA, the outer membrane strategy induced better B cell and T cell responses than cytoplasmic strategy. Most notably, the combination of two different expression strategies did not increase the immune response elicited as initially expected. Based on the advantages, deleterious or synergistic effects of different strategies identified in this study, I conclude that different construction strategies of recombinant Salmonella vaccine strains are needed for different forms of antigens (soluble or insoluble antigens). If the antigen (such as EGFP) is soluble and easily expressed in Salmonella, a low-copy plasmid-based strategy should be employed, as it can provoke both strong B cell and T cell responses with better plasmid stability. If a T cell response is preferred, a eukaryotic plasmid, or chromosome-based, cytoplasmic-expression strategy may achieve better results. For heterologous antigens that are likely to be expressed in an insoluble form inside Salmonella (such as HA), an outer membrane-targeting approach is recommended. In addition, I found that the combination of two expression strategies did not enhance the immune response, and hence I caution the use of such an approach.
published_or_final_version
Biochemistry
Doctoral
Doctor of Philosophy
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Oral vaccines"

1

Geneva), WHO Consultation on Oral Immunization of Dogs Against Rabies (5th 1994. Report of the 5th WHO Consultation on Oral Immunization of Dogs Against Rabies, Geneva, 20-22 June, 1994. Geneva: World Health Organization, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

WHO Consultation on Oral Immunization of Dogs Against Rabies (4th 1993 Geneva). Report of the 4th WHO Consultation on Oral Immunization of Dogs Against Rabies, Geneva, 14-15 June, 1993. Geneva: World Health Organization, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

World Health Organization (WHO). Second WHO consultation on oral immunization of dogs against rabies, Geneva, 6th July, 1990. Geneva: World Helath Organization, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Koprowski, Hilary. Vaccines--Advances in plant and microbial biotechnology infectious immunity and cancer therapy: Celebration of the 50th anniversary of the first vaccination of a Polish child against polio using Dr. Hilary Koprowski's oral polio vaccine, Warsaw University of Life Sciences-SGGW, Warsaw, Poland, November 28-29, 2008. Warsaw: Warsaw University of Life Sciences-SGGW, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

World Health Organization (WHO). Third WHO consultation on oral immunization of dogs against rabies, Geneva, 21-22 July, 1992. Geneva: World Helath Organization, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

World Health Organization (WHO). Report of WHO consultation on oral immunization of dogs against rabies, Geneva, 26-27 February, 1988. Geneva: World Helath Organization, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Organization, World Health. WHO/APHIS consultation on baits and baiting delivery systems for oral immunization of wildlife againstrabies, Colorado State University, Fort Collins, Colorado, 10-12 July, 1990. Geneva: World Health Organization, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

WHO Consultation on Requirements and Criteria for Field Trials on Oral Rabies Vaccination of Dogs and Wild Carnivores (1989 Geneva). Report of WHO Consultation on Requirements and Criteria for Field Trials on Oral Rabies Vaccination of Dogs and Wild Carnivores, held 1-2 March, 1989, in Geneva. Geneva: World Health Organization, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Workshop on Development of a Polio Antiviral and Its Potential Role in Global Poliomyelitis Eradication (2005 Washington, D.C.). Exploring the role of antiviral drugs in the eradication of polio: Workshop report. Washington, D.C: National Academies Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Coulson, Nicholas Michael. Expression of the protective antigen of bacillus anthracis in attenuated salmonella: A potential oral anthrax vaccine. [s.l.]: typescript, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Oral vaccines"

1

Hale, T. L., and S. B. Formal. "Oral Shigella Vaccines." In Current Topics in Microbiology and Immunology, 205–11. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-74529-4_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Tennant, Sharon M., Khitam Muhsen, and Marcela F. Pasetti. "Gut Immunology and Oral Vaccination." In Molecular Vaccines, 59–84. Vienna: Springer Vienna, 2013. http://dx.doi.org/10.1007/978-3-7091-1419-3_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gamazo, Carlos, and Juan M. Irache. "Antigen Delivery Systems as Oral Adjuvants." In Molecular Vaccines, 603–22. Cham: Springer International Publishing, 2013. http://dx.doi.org/10.1007/978-3-319-00978-0_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Giese, Sebastian, and Matthias Giese. "Oral Vaccination of Honeybees Against Varroa Destructor." In Molecular Vaccines, 269–78. Vienna: Springer Vienna, 2013. http://dx.doi.org/10.1007/978-3-7091-1419-3_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Macrina, Francis L. "Bacterial Diseases of the Oral Tissues." In Genetically Engineered Vaccines, 25–34. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3410-5_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kilian, Mogens, Jesper Reinholdt, Knud Poulsen, and Hans Lomholt. "IgA1 Proteases and Host-Parasite Relationships in the Oral Cavity." In Genetically Engineered Vaccines, 83–89. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3410-5_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Taubman, Martin A., and Daniel J. Smith. "Significance of Immune Responses to Oral Antigens in Dental Diseases." In Genetically Engineered Vaccines, 273–86. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3410-5_29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tagliabue, A. "Immune Response to Oral Salmonella Vaccines." In Current Topics in Microbiology and Immunology, 225–31. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-74529-4_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Czerkinsky, C., J. B. Sun, and J. Holmgren. "Oral Tolerance and Anti-Pathological Vaccines." In Defense of Mucosal Surfaces: Pathogenesis, Immunity and Vaccines, 79–91. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-59951-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Steele, Cherrilee, and Edward J. Shillitoe. "Oral Virus Infections: The Potential for Gene Transfer in Treatment and Prevention." In Genetically Engineered Vaccines, 35–42. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3410-5_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Oral vaccines"

1

ARNTZEN, CHARLES J. "PLANT-DERIVED ORAL VACCINES: FROM CONCEPT TO CLINICAL TRIALS." In International Seminar on Nuclear War and Planetary Emergencies 25th Session. Singapore: World Scientific Publishing Co. Pte. Ltd., 2001. http://dx.doi.org/10.1142/9789812797001_0014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wieckowski, Sébastien, Lilli Podola, Marco Springer, Iris Kobl, Zina Koob, Caroline Mignard, Amine Adda Berkane, et al. "Abstract 4558: Immunogenicity and antitumor efficacy of live attenuatedSalmonellatyphimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-4558.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lim, Kue Peng, Chai Phei Gan, Chan Eng Chong, Rosnah Binti Zain, Mannil Thomas Abraham, Zainal Ariff Abdul Rahman, Soo-Hwang Teo, et al. "Abstract 1573: MAGED4B drives oral carcinogenesis and is a promising peptide vaccine target for the treatment of oral squamous cell carcinoma." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1573.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ribeiro, André, Miguel O Herrera, and Elezer Lemes. "Risk assessment: prospective approach on integrity inspection line of an oral vaccine’s primary package." In III Seminário Anual Científico e Tecnológico de Bio-Manguinhos. Instituto de Tecnologia em Imunobiológicos, 2016. http://dx.doi.org/10.35259/isi.sact.2016_28402.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Clark, Anna-Maria A., and M. R. Young. "Abstract 4763: Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate: immunologic effects in mice bearing carcinogen-induced premalignant oral lesions." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-4763.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bell, R. Bryan, Rom Leidner, Carlo B. Bifulco, Christopher Dubay, Tarsem Moudgil, Sam Bookhardt, Glenna McDonnell, et al. "Abstract 38: Development of a DC-targeted microvesicle vaccine to intercept the progression of oral preneoplasia to cancer." In Abstracts: AACR-AHNS Head and Neck Cancer Conference: Optimizing Survival and Quality of Life through Basic, Clinical, and Translational Research; April 23-25, 2017; San Diego, CA. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1557-3265.aacrahns17-38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Eddicks, M., A. Palzer, M. Ritzmann, S. Hörmannsdorfer, and K. Heinritzi. "Evaluation of the tolerability of the Salmonella Typhimurium live vaccine Salmoporc® for oral administration in three day old piglets." In Seventh International Symposium on the Epidemiology and Control of Foodborne Pathogens in Pork. Iowa State University, Digital Press, 2007. http://dx.doi.org/10.31274/safepork-180809-115.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Beachler, Daniel C., Aimee R. Kreimer, Mark Schiffman, Rolando Herrero, Sholom Wacholder, Ana Cecilia Rodriguez, Douglas R. Lowy, et al. "Abstract 4680: Efficacy of the HPV16/18 vaccine against cervical, anal, and oral HPV infection among women with and without previous HPV16/18 exposure." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4680.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zhong, Zhenyu, Yougang Zhai, and Liang Qiao. "Abstract 1576: An oral therapeutic vaccine for colorectal cancer effectively eradicates intestinal tumors independently of target tumor-antigen specific immunities in APCMin/+ hCEA mice." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1576.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Oral vaccines"

1

Ross, Gordon D. Development of an Oral Barley Beta-Glucan Adjuvant That Augments the Tumoricidal Activity of Antibodies or Vaccines Used for the Immunotherapy of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 2003. http://dx.doi.org/10.21236/ada417775.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Albornoz, Jorge T. Field Testing of Meningococcal Group B Vaccine and Oral Cholera Vaccine. Fort Belvoir, VA: Defense Technical Information Center, October 1995. http://dx.doi.org/10.21236/ada324898.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Johnson, Anna K., Roy A. Edler, J. Tyler Holck, Brad V. Lawrence, and Robert G. Baker. Drinking Behavior of Nursery Pigs for Oral Vaccine Administration. Ames (Iowa): Iowa State University, January 2007. http://dx.doi.org/10.31274/ans_air-180814-626.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Reisfeld, Ralph A. An Oral DNA Vaccine Encoding Endoglin Eradicates Breast Tumors by Blocking Their Blood Supply. Fort Belvoir, VA: Defense Technical Information Center, May 2006. http://dx.doi.org/10.21236/ada455983.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Reisfeld, Ralph A. An Oral DNA Vaccine Encoding Endoglin Eradicates Breast Tumors by Blocking Their Blood Supply. Fort Belvoir, VA: Defense Technical Information Center, May 2007. http://dx.doi.org/10.21236/ada474671.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pinto, Angelo J. Efficacy of the Heat-Labile Enterotoxin from Escherichia Coli as an Adjuvant for a HSV-2 Inactivated Oral Vaccine. Fort Belvoir, VA: Defense Technical Information Center, March 1996. http://dx.doi.org/10.21236/ada312064.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Levine, Myron M. Field Trial of Attenuated Salmonella typhi Live Oral Vaccine Ty21a in Liquid and Enteric-Coated Formulations and Epidemiological Survey for Incidence of Diarrhea Due to Shigella Species. Fort Belvoir, VA: Defense Technical Information Center, April 1992. http://dx.doi.org/10.21236/ada252089.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Oral vaccines' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography